Pharmacotherapeutic follow-up on outcomes for crohn’s disease patient with multimorbidity: case report
DOI:
https://doi.org/10.30968/rbfhss.2017.084.002Keywords:
Doença de Crohn, Acompanhamento farmacoterapêutico, Intervenções farmacêuticas.Abstract
Objective: This case report aimed to assess the viability of pharmacotherapeutic follow-up of a Crohn’s Disease outpatient with multimorbidity, for the implantation of a pharmaceutical care service for inflammatory bowel disease patients in a University Hospital. Method: Data regarding associated pathologies and medication history were collected during six months in pharmaceutical consultations, also information on medical charts with due authorization (no. 510.998). Assessment of drug related problems was done with aid of a drug interaction checker and Naranjo adverse drug reaction probability scale, and also Crohn’s disease activity index used during clinical follow-up. Results: A 49-year-old female CD patient with type 2 diabetes, hypertension and glaucoma was followed-up. It was identified adverse drug reaction to metformin resulting in noncompliance with therapy, with posterior resolution of this problem after intervention with health team and patient education about change in the drug scheduling. Conclusions: Thus, pharmacotherapeutic follow-up effectively contributed to the execution of the right interventions: education regarding therapy, change in the antidiabetic drug scheduling and identification of drug adverse reaction. Pharmacotherapeutic follow-up brings the pharmacist to the healthcare team on managing Crohn’s disease and multimorbidities, enhancing adherence and reducing complications, with aid of pharmaceutical interventions. This case also showed the viability to implant this pharmaceutical service in the hospital, expanding it to other inflammatory bowel disease patients.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
